SPRO

Spero Therapeutics, Inc.

NasdaqHealthcarePHARMACEUTICAL PREPARATIONS

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$00 buys
Total selling$42.5k1 sale
Net open-market−$42.5kBuying minus selling
Active insiders2Distinct reporting owners

SPRO transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Rajavelu Esther
SR
SR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$42.5kView disclosure →
Ho William
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Nov 10, 2026

Open-market transaction mix · 1 transactions in the selected period
0 buys0%·100%1 sells

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026000$0$0$0
Nov 2026011$0$42,485.04−$42,485.04

Distinct insiders active

Reporting-owner CIKs by month · peak Nov 2026 (2)
Oct 2026: 0 insidersNov 2026: 2 insiders
Oct 2026Nov 2026
2distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
2 insiders
  • RE
    Rajavelu EstherSR · 0 buys · 1 sale · 0 awards (A)
    −$42.5klast Nov 10
  • HW
    Ho WilliamDIR · 0 buys · 0 sales · 1 award (A)
    $0last Nov 10
Filing, role and holdings details

Filing-only signals

Deterministic matches in the selected period

Recent filing activity
Most recent 2 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy—
Largest sale$42.5k
10b5-1 detected0
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
2transactionstxns
  • A · Grants / awards · dominant1 · 50%
  • S · Open-market sells1 · 50%

Activity by reported role

A joint filing can contribute to multiple roles
Director1
SR1

Reported Holdings After

Separated by insider, security, and ownership type

Rajavelu EstherCommon Stock · Direct
946k946kNov 9, 2026Nov 9, 2026
946,000Nov 9, 2026
Ho WilliamStock Option (right to buy) · Direct
100k100kNov 10, 2026Nov 10, 2026
100,000Nov 10, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
1 active days
Oct 16 → Nov 16
LessMore

Spero Therapeutics, Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at Spero Therapeutics, Inc.?

Rajavelu Esther, HO WILLIAM.

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

Rajavelu Esther reported a sale on Nov 9, 2026 valued at $42.5k. Read the SEC filing.

What is the recent purchase and sale balance?

Net open-market selling in the selected period was $42,485.04. Sales can occur for many non-investment reasons.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.